|
1
|
Mazeh H and Sippel RS: Familial
nonmedullary thyroid carcinoma. Thyroid. 23:1049–1056. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Alsanea O, Wada N, Ain K, Wong M, Taylor
K, Ituarte PH, Treseler PA, Weier HU, Freimer N, Siperstein AE, et
al: Is familial non-medullary thyroid carcinoma more aggressive
than sporadic thyroid cancer? A multicenter series. Surgery.
128:1043–1051. 2000.
|
|
3
|
Uchino S, Noguchi S, Kawamoto H, Yamashita
H, Watanabe S and Shuto S: Familial nonmedullary thyroid carcinoma
characterized by multifocality and a high recurrence rate in a
large study population. World J Surg. 26:897–902. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mazeh H, Benavidez J, Poehls JL,
Youngwirth L, Chen H and Sippel RS: In patients with thyroid cancer
of follicular cell origin, a family history of nonmedullary thyroid
cancer in one first-degree relative is associated with more
aggressive disease. Thyroid. 22:3–8. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Park YJ, Ahn HY, Choi HS, Kim KW, Park J
and Cho BY: The long-term outcomes of the second generation of
familial nonmedullary thyroid carcinoma are more aggressive than
sporadic cases. Thyroid. 22:356–362. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee YM, Yoon JH, Yi O, Sung TY, Chung KW,
Kim WB and Hong SJ: Familial history of non-medullary thyroid
cancer is an independent prognostic factor for tumor recurrence in
younger patients with conventional papillary thyroid carcinoma. J
Surg Oncol. 109:168–173. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McDonald TJ, Driedger AA, Garcia BM, Van
Uum SH, Rachinsky I, Chevendra V, Breadner D, Feinn R, Walsh SJ and
Malchoff CD: Familial papillary thyroid carcinoma: A retrospective
analysis. J Oncol. 2011:9487862011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maxwell EL, Hall FT and Freeman JL:
Familial non-medullary thyroid cancer: A matched-case control
study. Laryngoscope. 114:2182–2186. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ito Y, Kakudo K, Hirokawa M, Fukushima M,
Yabuta T, Tomoda C, Inoue H, Kihara M, Higashiyama T and Uruno T:
Biological behavior and prognosis of familial papillary thyroid
carcinoma. Surgery. 145:100–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Robenshtok E, Tzvetov G,
Grozinsky-Glasberg S, et al: Clinical characteristics and outcome
of familial nonmedullary thyroid cancer: A retrospective controlled
study. Thyroid. 21:43–48. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Moses W, Weng J and Kebebew E: Prevalence,
clinicopathologic features, and somatic genetic mutation profile in
familial versus sporadic nonmedullary thyroid cancer. Thyroid.
21:367–371. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pinto AE, Silva GL, Henrique R, Menezes
FD, Teixeira MR, Leite V and Cavaco BM: Familial vs sporadic
papillary thyroid carcinoma: A matched-case comparative study
thening similar clinical/prognostic behaviour. Eur J Endocrinol.
170:321–327. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Malchoff CD and McDonald TJ: Is familial
nonmedullary thyroid carcinoma more aggressive than sporadic
nonmedullary thyroid carcinoma? Thyroid. 24:782–783. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Charkes ND: On the prevalence of familial
nonmedullary thyroid cancer in multiply affected kindreds. Thyroid.
16:181–186. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Giordano TJ, Kuick R, Thomas DG, Misek DE,
Vinco M, Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K, et al:
Molecular classification of papillary thyroid carcinoma: Distinct
BRAF, RAS, and RET/PTC mutation-specific gene expression profiles
discovered by DNA microarray analysis. Oncogene. 24:6646–6656.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shaha AR: TNM classification of thyroid
carcinoma. World J Surg. 31:879–887. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Natalicchio MI, Improta G, Zupa A, Cursio
OE, Stampone E, Possidente L, Teresa Gerardi AM, Vita G, Martini M,
Cassano A, et al: Pyrosequencing evaluation of low-frequency KRAS
mutant alleles for EGF receptor therapy selection in metastatic
colorectal carcinoma. Future Oncol. 10:713–723. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vriens MR, Schreinemakers JM, Suh I,
Guerrero MA and Clark OH: Diagnostic markers and prognostic factors
in thyroid cancer. Future Oncol. 5:1283–1293. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bauer AJ: Clinical behavior and genetics
of nonsyndromic, familial nonmedullary thyroid cancer. Front Horm
Res. 41:141–148. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Champion KJ, Bunag C, Estep AL, Jones JR,
Bolt CH, Rogers RC, Rauen KA and Everman DB: Germline mutation in
BRAF codon 600 is compatible with human development: De novo
p.V600G mutation identified in a patient with CFC syndrome. Clin
Genet. 79:468–474. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cirstea IC, Kutsche K, Dvorsky R, Gremer
L, Carta C, Horn D, Roberts AE, Lepri F, Merbitz-Zahradnik T, König
R, et al: A restricted spectrum of NRAS mutations causes Noonan
syndrome. Nat Genet. 42:27–29. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Son EJ and Nosé V: Familial follicular
cell-derived thyroid carcinoma. Front Endocrinol (Lausanne).
3:612012.PubMed/NCBI
|
|
23
|
Muzza M, Degl'Innocenti D, Colombo C,
Perrino M, Ravasi E, Rossi S, Cirello V, Beck-Peccoz P, Borrello MG
and Fugazzola L: The tight relationship between papillary thyroid
cancer, autoimmunity and inflammation: Clinical and molecular
studies. Clin Endocrinol (Oxf). 72:702–708. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rotondi M, Coperchini F, Pignatti P,
Sideri R, Groppelli G, Leporati P, La Manna L, Magri F, Mariotti S
and Chiovato L: Interferon-γ and tumor necrosis factor-α sustain
secretion of specific CXC chemokines in human thyrocytes: A first
step toward a differentiation between autoimmune and tumor-related
inflammation? J Clin Endocrinol Metab. 98:308–313. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bozec A, Lassalle S, Hofman V, Ilie M,
Santini J and Hofman P: The thyroid gland: A crossroad in
inflammation-induced carcinoma? An ongoing debate with new
therapeutic potential. Curr Med Chem. 17:3449–3461. 2010.
|
|
26
|
Medici M, Porcu E, Pistis G, Teumer A,
Brown SJ, Jensen RA, Rawal R, Roef GL, Plantinga TS, Vermeulen SH,
et al: Identification of novel genetic Loci associated with thyroid
peroxidase antibodies and clinical thyroid disease. PLoS Genet.
10:e10041232014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Handkiewicz-Junak D, Czarniecka A and
Jarzab B: Molecular prognostic markers in papillary and follicular
thyroid cancer: Current status and future directions. Mol Cell
Endocrinol. 322:8–28. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jang EK, Song DE, Sim SY, Kwon H, Choi YM,
Jeon MJ, Han JM, Kim WG, Kim TY, Shong YK, et al: NRAS codon 61
mutation is associated with distant metastasis in patients with
follicular thyroid carcinoma. Thyroid. 24:1275–1281. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Elisei R, Viola D, Torregrossa L, Giannini
R, Romei C, Ugolini C, Molinaro E, Agate L, Biagini A, Lupi Cu, et
al: The BRAF(V600E) mutation is an independent, poor prognostic
factor for the outcome of patients with low-risk intrathyroid
papillary thyroid carcinoma: single-institution results from a
large cohort study. J Clin Endocrinol Metab. 97:4390–4398. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li C, Aragon Han P, Lee KC, Lee LC, Fox
AC, Beninato T, Thiess M, Dy BM, Sebo TJ, Thompson GB, et al: Does
BRAF V600E mutation predict aggressive features in papillary
thyroid cancer? Results from four endocrine surgery centers. J Clin
Endocrinol Metab. 98:3702–3712. 2013. View Article : Google Scholar
|
|
31
|
Walczyk A, Kowalska A, Kowalik A, Sygut J,
Wypiórkiewicz E, Chodurska R, Pięciak L and Góźdź S: The
BRAF(V600E) mutation in papillary thyroid microcarcinoma: Does the
mutation have an impact on clinical outcome? Clin Endocrinol (Oxf).
80:899–904. 2014. View Article : Google Scholar : PubMed/NCBI
|
